Abstract
Immunotherapy with toll like receptor 9 (TLR9) agonist CpG ODN offers an emergent strategy to treat life‐threatening malignant glioma. CpG is typically applied invasively by intracranial and intrathecal administration which induces not only poor compliance and lessened potency but also possibly strong adverse effects and immunotoxicity. Here, it is reported that immunotherapy of murine LCPN glioma is greatly boosted by polymersome‐steered intravenous and intranasal brain delivery of CpG. CpG is efficiently loaded in apolipoprotein E peptide‐directed polymersomes to give blood‐brain barrier permeable and glioma and cervical lymph node‐homing CpG nano‐immunoadjuvant (t‐NanoCpG) which strongly stimulates the maturation of dendritic cells, antigen cross‐presentation, and production of proinflammatory cytokines in vivo. Intriguingly, both intravenous and intranasal administration of t‐NanoCpG brings about significant survival benefits in murine LCPN glioma‐bearing mice while free CpG and nontargeted CpG nano‐immunoadjuvant (NanoCpG) afford modest therapeutic effects. Moreover, combination of t‐NanoCpG with radiotherapy further boosts the immunotherapeutic effects leading to more improved survival rate of mice. This intelligent brain‐permeable nano‐immunoadjuvant provides a new, minimally invasive and highly potent strategy for immunotherapy of glioma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
